Sequencing Therapies in Indolent Lymphomas
Presented by Philip A. Thompson, MB, BS, and Lisa Nodzon, PhD, ARNP, AOCNP®
The University of Texas MD Anderson Cancer Center, Houston, Texas; and Moffitt Cancer Center, Tampa, Florida
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2019;10(3):280–286 |
© 2019 Harborside™
Several targeted agents have recently emerged for the treatment chronic lymphocytic leukemia and follicular lymphoma, which has made treatment selection more complex. Philip A. Thompson, MB, BS, and Lisa Nodzon, PhD, ARNP, AOCNP®, described the growing therapeutic landscape of these diseases, as well as how to recognize and manage the toxicities commonly seen with targeted agents.
For access to the full length article, please sign in